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ANTI-dsDNA ANTIBODIES AND LUPUS
NEPHRITIS
Antibodies against DNA were de-
scribed in 1957 by four independent re-
search groups (1–4). Scientists at that
time could not foresee that the discovery
of antibodies to double-stranded DNA
(dsDNA) would have an immense im-
pact on our understanding of origin and
regulation of autoimmunity in general,
and more specifically on autoimmune-
mediated inflammation.
Soon after their discovery, it was
shown that anti-dsDNA autoantibodies
were associated with lupus nephritis.
This finding was supported by three
facts: (i) DNA bound glomerular colla-
gen (5,6); (ii) the nephritogenic antibod-
ies were specific for DNA (7,8); and (iii)
anti-dsDNA antibodies could be eluted
from the nephritic kidneys (7,9–14; re-
viewed in [15]).
Despite several decades of research,
there is no consensus on the basic mecha-
nisms that promote lupus nephritis. Data
on cross-reactivity of anti-dsDNA anti-
bodies led to the interpretation that renal
structures bound nephritogenic autoanti-
bodies in vivo (reviewed in [15,16]; for de-
tails, see below). However, renal targets
for anti-dsDNA antibodies can also be
their homologous antigens (dsDNA or
chromatin fragments) generated during
apoptosis (reviewed in [15,17]). The re-
lease and accumulation of apoptotic chro-
matin fragments under normal physiolog-
ical conditions is prevented by the rapid
and silent clearance of apoptotic cells by
macrophages. Pathological processes in
systemic lupus erythematosus (SLE) that
lead to accumulation and exposure of im-
munogenic chromatin fragments may in-
clude aberrant apoptosis, impaired clear-
ance of apoptotic cells and reduced
chromatin fragmentation (18–20).
Early mesangial nephritis is character-
ized by mesangial deposits of chromatin
fragments in complex with antibodies to
dsDNA, whereas advanced stages of
lupus nephritis are characterized by
deposition of immune complexes in both
the mesangial matrix and the glomerular
basement membrane (GBM) (21). More-
over, we have demonstrated that ad-
vanced stages of lupus nephritis are as-
sociated in time with an almost
complete and selective silencing of the
renal DNaseI gene (22–24), the major 
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endonuclease in the kidney (25), which
is accompanied by a reduced chromatin
fragmentation capacity in the nephritic
kidneys (26).
THE PARADOX OF ANTI-dsDNA
ANTIBODIES: ARE THEY REALLY
PATHOGENIC?
Not all individuals with anti-dsDNA
antibodies in their circulation develop
nephritis, although anti-dsDNA antibod-
ies are believed to be directly involved in
the nephritic process (16). One model
proposes that only those anti-dsDNA an-
tibodies that cross-react with intrinsic
glomerular antigens induce lupus
nephritis, which could explain why not
all patients with anti-dsDNA antibodies
develop the disease. Another model
states that the nephritogenic potential of
anti-dsDNA/anti-chromatin antibodies
is exerted because the antibodies target
extracellular chromatin fragments in
glomeruli (15). This result would explain
that anti-dsDNA antibodies are patho-
genic only in situations where chromatin
is exposed in glomeruli.
Cross-reacting anti-dsDNA antibodies
may react with, for example, α-actinin
(27,28), extracellular matrix components
(9,11,29), cell surface structures (30,31)
and entactin (32). Until now, no results
from prospective multicenter studies
have been published that analyze in an
unbiased way the impact of the de-
scribed cross-reactive antibodies in the
development of lupus nephritis. In one
prospective clinical study in patients
with lupus nephritis, a relationship was
found between anti-dsDNA/anti-
 chromatin antibodies and renal parame-
ters, which, for example, was not ob-
served for anti-α-actinin antibodies (33).
Lack of impact of anti-α-actinin antibod-
ies on nephritis was also demonstrated
in the (NZBxNZW)F1 (BW) mouse
model for lupus nephritis, since antibod-
ies eluted from diseased kidneys hardly
bound α-actinin, whereas a large fraction
of the antibodies bound dsDNA, his-
tones and nucleosomes (10). Whether an
anti-dsDNA/anti-chromatin antibody
initiates and executes a pathogenic activ-
ity might therefore be determined by the
availability of chromatin fragments
within glomeruli and not by the poten-
tial cross-reactivity of these antibodies. In
the absence of extracellular chromatin,
the anti-dsDNA antibodies remain non-
pathogenic epiphenomena, aside from
their diagnostic potential for SLE.
WHAT IS THE EVIDENCE THAT 
CROSS-REACTION OF ANTI-dsDNA
ANTIBODIES WITH INTRINSIC RENAL
ANTIGENS IS A SINE QUA NON IN THE
PROCESS OF LUPUS NEPHRITIS?
The cross-reaction model to explain
the nephritogenic potential of anti-
dsDNA antibodies shows some caveats.
Dual specificity per se does not identify
which one of the cross-reactive renal lig-
ands actually are bound by these anti-
bodies in vivo. Even proving that anti-
bodies eluted from nephritic kidneys
possess dual specificity, for example, by
demonstrating that eluted anti-dsDNA
antibodies cross-react with renal
nonchromatin target structures such as
α-actinin (27,28), laminin (29) or entactin
(32), does not reveal which of the target
structures these antibodies actually bind
in vivo.
To determine the actual in vivo target
structures for anti-dsDNA antibodies, dif-
ferent high-resolution analytical assays
such as colocalization immune electron
microscopy (IEM) techniques can be used
(34,35). For example, colocalization IEM
has the potential to reveal whether
in vivo–bound IgG colocalizes or not with
antibodies to dsDNA, histones and other
chromatin-associated proteins added to
the kidney sections in vitro. If a glomeru-
lar target antigen is a nonchromatin struc-
ture, but an intrinsic target structure,
binding of anti-dsDNA/ chromatin anti-
bodies in vivo should be traced to the ex-
tracellular matrix, including the glomeru-
lar basement membrane (GBM), and not
to deposited chromatin present as elec-
tron dense structures (EDSs) in the GBM
(35). When we traced IgG bound in vivo to
GBM-associated EDSs, we observed IgG
binding confined to EDSs (35), which
argue against in vivo binding of antibodies
to, for example, laminin (29) or entactin
(32). In addition, we could not demon-
strate the presence of laminin and 
α-actinin within EDSs in murine (10,35)
and human lupus nephritis (34). Thus,
there seems to be no direct evidence that
cross-reaction of anti-dsDNA antibodies
with intrinsic renal antigens is important
in the process of lupus nephritis.




If anti-dsDNA antibodies are so central
in the pathogenesis of lupus nephritis as
we believe, and if cross-reaction of the
antibodies with renal structures is a pre-
requisite for the pathogenic potential of
the antibodies as others believe, then the
immune system must be stimulated in a
way that preserves the dual specificity of
the antibodies over time.
Generation of antibody specificity is a
result of several stochastic processes from
random heavy-chain V-D-J and light-
chain V-J gene segment recombination
(combinatorial diversity), nontemplated
nucleotide insertion  (functional diver-
sity), to heavy- and light-chain associa-
tion and to somatic hypermutation
(36,37) (for a scholarly overview, see rele-
vant chapters by Murphy et al. [38]).
These stochastic processes do not permit
discrimination between self and nonself
antigens, and generation of antibodies
with specificity for dsDNA is therefore
not a rare event (39–43). These anti-
dsDNA antibodies are often observed to
be cross-reacting or even polyspecific an-
tibodies (44–48).
Many of the studies on the potential
nephritogenic effect of cross-reactive an-
tibody populations are performed by
using monoclonal antibodies. In contrast
to the dynamic affinity maturation as a
consequence of continuous somatic mu-
tations of antibodies during a humoral
immune response (49,50), the specificity
and affinity of monoclonal antibodies are
frozen in time and therefore mostly re-
tain their (dual) specificity that was pres-
ent at the time of hybridoma cell genera-
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tion. It may be argued whether the use of
cross-reactive monoclonal anti-dsDNA
antibodies to study their pathogenic po-
tential is relevant to understand how
anti-dsDNA antibodies bind in lupus
nephritis. The biological meaning of so-
matic hypermutation is to increase affin-
ity for the immunogen (in the case of
SLE, components of chromatin) and to
limit poly-specificity. Because in lupus
nephritis both sets of possible target
structures (that is, intrinsic glomerular
structures and DNA/chromatin compo-
nents) are present in the glomerulus
(15,35), the following three considera-
tions must be taken into account to clar-
ify the role of cross-reactivity in lupus
nephritis: (i) Is a given cross-reaction be-
tween DNA and a glomerular antigen re-
tained during affinity maturation of the
immune response? (ii) If cross-reaction is
significant, and a given cross-reactive
non-DNA glomerular antigen is sup-
posed to bind the antibody, then are the
affinities for both the DNA and the non-
DNA antigen different? Theoretically, the
affinity should be higher for the cross-
 reactive antigen than for DNA if binding
to the cross-reactive antigen is the inter-
action that mediates the development of
nephritis. (iii) Robust assays must be
used to clarify the chemical nature and
localization of glomerular structures tar-
geted in vivo by nephritogenic anti-
dsDNA antibodies. This step can be per-
formed by electron microscopy and
coherent studies of cross-reactive anti-
bodies in sera and in renal eluates of dis-
eased individuals.
ARE ANTI-dsDNA ANTIBODIES
REQUIRED FOR THE DEVELOPMENT OF
LUPUS NEPHRITIS?
Not all patients with lupus nephritis
have detectable levels of anti-dsDNA an-
tibodies in their circulation, indicating
that lupus nephritis is not always linked
to the presence of these antibodies. This
has been experimentally demonstrated in
murine models of lupus nephritis, where
in fact the activity of T cells accounted for
the kidney injury (51,52). Consistent with
this latter observation, the production of
anti-chromatin autoantibodies is not ab-
solutely required for the development of
lupus nephritis (53). Thus, the pathogene-
sis of lupus nephritis includes elements
of antibody-independent processes.
Such observations may explain the re-
sults of the Lupus Nephritis Assessment
with Rituximab (LUNAR) study (that is,
an anti–B-cell therapy) (54). Although rit-
uximab reduced CD19+ B cells and re-
sulted in a relative improvement of
serum levels of complement (C3 and C4)
and reduced anti-dsDNA antibody lev-
els, renal response rates were similar in
the treatment and placebo groups. Thus,
the nephritic process remained largely
unaffected during the treatment period.
This result may theoretically be ex-
plained in two ways: either reminiscent
levels of anti-dsDNA antibodies were
sufficient to maintain nephritis, or infil-
trating autoimmune (possibly cytotoxic)
T cells in the kidney may have been in-
volved in a way that maintained the
nephritic process, since T cells are not af-
fected by rituximab. However, from the
LUNAR study design, the role of T cells
remains elusive, since renal biopsies
were not analyzed at the end point. Nev-
ertheless, although anti-dsDNA antibod-
ies may not always be required in pro-
gressive lupus nephritis, most data so far
indicate that anti-dsDNA antibodies are
inflicted in the disease severity (8,55–57).
A CENTRAL ROLE FOR CHROMATIN IN
THE DEVELOPMENT OF LUPUS NEPHRITIS
Our data in BW mice support the con-
cept that the pathogenesis of murine
lupus nephritis is characterized by two
distinct stages. Late forms of membra-
noproliferative lupus nephritis evolve as
a consequence of early mesangial lupus
nephritis (24,58). In the next sections, we
will outline the molecular and transcrip-
tional mechanisms accounting for this
two-stepped nephritic process.
BASIC OBSERVATIONS IN EARLY
MURINE MESANGIAL LUPUS NEPHRITIS
In several studies, we showed that
chromatin fragments serve as central tar-
gets for nephritogenic anti-dsDNA/anti-
nucleosome antibodies in all stages of
lupus nephritis (35,59,60). The early phase
of lupus nephritis correlated with deposi-
tion of chromatin fragment–IgG com-
plexes in the mesangial matrix. By high-
resolution analytical approaches, such as
IEM, colocalization IEM and colocaliza-
tion terminal deoxynucleotidyl trans-
ferase dUTP nick end-labeling (TUNEL)
IEM, IgG was never observed to bind in
vivo directly to the GBM or to the mesan-
gial matrix. But IgG did bind to TUNEL-
positive EDSs associated with glomerular
matrices and membranes (34,35) (Figure 1).
This result was demonstrated in murine
lupus nephritis (35) and was verified in
patients with lupus nephritis (34).
The link between production of anti-
dsDNA antibodies and chromatin de-
posits in the mesangium indicates that
the antibodies were directly responsible
for this process (24), since we never ob-
served chromatin in glomerular matrices
and membranes in anti-dsDNA antibody-
negative BW mice (22,24).
PROGRESSION OF MURINE LUPUS
NEPHRITIS: A POSSIBLE ROLE FOR
RENAL DNASEI
At a certain time point, clinically silent
mesangial nephritis progresses into end-
stage organ disease. This point was char-
acterized by the deposition of chromatin
fragment–IgG complexes in the GBM
and by severe proteinuria. The progres-
sion was strongly associated with a loss
of renal DNaseI gene expression at both 
the transcriptional and the translational
levels and with a severe loss of renal
DNaseI enzyme activity as well. Silencing
of the renal DNaseI gene was demon-
strated by Western blot, zymography, im-
munohistochemistry, immunofluores-
cence, quantitative polymerase chain
reaction and unpublished Affymetrix mi-
croarray analyses (22–24,58). Because
DNaseI is required for chromatin break-
down during apoptosis as well as necro-
sis (61,62), loss of this enzyme activity
may lead to accumulation of apoptotic
chromatin fragments in glomeruli. In line
with this result, local accumulation of
chromatin fragment–anti-dsDNA anti-
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body complexes in GBM may be the core
factor that imposes progressive renal in-
flammation in SLE (23,35,63).
The role of reduced DNaseI in the
pathogenesis of SLE has been discussed
for decades. This discussion led to the
opinion that DNaseI could be a promising
drug for substitutive therapy to prevent
autoimmunity (64–66). Studies aimed at
analyzing this option were performed in
both BW mice (64,66) and human patients
(65). However, this idea fell into oblivion
for years because the treatment largely
failed. Injection of DNaseI in prenephritic
BW mice delayed, but did not prevent,
the disease in one study (64). In another
study, administration of DNaseI in BW
mice did not affect development or pro-
gression of lupus nephritis (66). Similarly,
intravenous or subcutaneous administra-
tion of recombinant human DNaseI in pa-
tients with lupus nephritis class III–V did
not affect kidney function or activity of
the disease (65). These studies demon-
strated indirectly that serum DNaseI had
little or no influence on degradation of
apoptotic chromatin in the kidney (61).
Treatment failure may thus indicate that
DNaseI in the extracellular compartments
has a poor impact on chromatin deposited
in the GBM.
Data from our laboratory as well as
from other laboratories provide the basis
for the following conclusions: (i) DNaseI
is strongly expressed in healthy kidneys
(67) (see also gene expression profiles from
the BioGPS portal at http://biogps.org)
and account for 80% of total renal en-
donuclease activity (25); (ii) DNaseI ex-
pression is selectively reduced compared
with other endonucleases expressed in
nephritic kidneys (23); (iii) DNaseI expres-
sion is furthermore selectively silenced in
affected kidneys and not in other organs
and tissues that express DNaseI (23); (iv)
silencing of the renal DNaseI gene is the
result of an active regulation of gene ex-
pression and not caused by cell death,
since other renal genes analyzed so far are
not silenced but are expressed at normal
levels (23,58); and (v) there is a highly sig-
nificant inverse correlation between loss
of DNaseI enzyme activity and progres-
sion of lupus nephritis, and with deposi-
tion of chromatin fragments in the GBM,
while with normal or subnormal renal
DNaseI gene expression, no deposits in
GBM were observed (24,58). These con-
clusions do not, however, clarify if extra-
cellular chromatin deposition secondary
to loss of renal DNaseI is a direct or indi-
rect consequence of local or systemic tis-
sue damage and if the formation of anti-
dsDNA antibodies in complex with
chromatin is a secondary event that
 participates in development of nephritis.
What the data demonstrate, however, is
that chromatin–IgG complexes are in-
volved in progression of lupus nephritis.
1 6 4 |  S E R E D K I N A E T  A L .  |  M O L  M E D  1 9 : 1 6 1 - 1 6 9 ,  2 0 1 3
L U P U S  N E P H R I T I S :  A N  E M E R G I N G  C O N C E P T
Figure 1. Nephritogenic antibodies target chromatin exposed in glomeruli in the context
of lupus nephritis as demonstrated by IEM. Nephritogenic antibodies bind chromatin
fragments observed as EDSs in the GBM in murine (A–C) and human (D–F) lupus nephri-
tis. In vivo–bound IgG antibodies are confined to EDSs present in the mesangial matrix
and in the GBM in murine and human nephritis (A and D, respectively), as shown by IEM.
In (A) and (D), the IgG molecules are stained with 5-nm gold particles. Their presence is
confined to EDSs. In (B) and (E), the EDSs are shown to contain nicked DNA (traced by 
10-nm gold particles) that colocalizes with in vivo–bound IgG (traced by 5-nm gold par-
ticles), as shown by a combination of IEM and the TUNEL assay (colocalization TUNEL IEM,
(B) and (E) for murine and human nephritis, respectively). The colocalization TUNEL IEM
was specific, since the assay performed in the absence of terminal deoxynucleotidyl
transferase resulted in detection of in vivo–bound IgG (5 nm gold), but not in nicked DNA
(absence of 10 nm gold, (C) and (F) for murine and human nephritis, respectively). These
data show that targets for glomerular in vivo–bound IgG antibodies are observed as
EDSs and contain DNA. The panels are previously unpublished images generated from
the project linked to references (34) and (35) in the current article.
BIOLOGICAL CONSEQUENCES OF
LOSS OF DNASEI EXPRESSION IN
NEPHRITIC KIDNEYS
The biological consequences of renal
DNaseI shutdown and reduced chromatin
fragmentation, beyond a classic immune
complex disease, may also involve activa-
tion of cells of the innate immune system.
Recently, we performed detailed analyses
of renal expression of toll-like receptors
(TLR) 7–9 and the necrosis-related Clec4e
receptor in murine and human lupus
nephritis. Furthermore, analyses were
performed to determine if upregulation of
matrix metalloproteases (MMPs) correlate
with increased TLR7–9/Clec4e expression
(68), since stimulation of TLR has been
shown to upregulate certain MMPs in, for
example, macrophages (69,70). For exam-
ple, engagement of TLRs can upregulate
the expression of proinflammatory cy-
tokines (tumor necrosis factor [TNF]α and
interferon [IFN]γ [71]) and interleukins
(72,73) that directly induce expression of
MMPs (71–73). Alternatively, incomplete
clearance and degradation of apoptotic
cells may transform them into secondary
necrotic cell debris (63,74). This step may
be significant, since necrotic cell debris
contains SAP130, which serves as a ligand
for the inflammation-related receptor
Clec4e (75,76). Downstream signaling in-
duced by SAP130-Clec4e receptor interac-
tion also promotes production of proin-
flammatory cytokines (77) and a
consequent upregulation of MMP expres-
sion. Increased MMP activity may (be-
cause of their gelatinase activity) disinte-
grate glomerular membranes (78). MMPs
may therefore open membrane structures
and facilitate deposition of chromatin
fragment–IgG complexes in both the
mesangial matrix and in the GBM.
We demonstrated that the expression
of TLR7–9 and Clec4e was significantly
upregulated in the BW mice at the same
time when we observed the deposition of
chromatin–IgG complexes in the GBM
and the loss of renal DNaseI gene expres-
sion (68). We hypothesize that the pres-
ence of chromatin can be responsible for
the increased TLR7–9/Clec4e expression.
Thus, silencing of renal DNaseI expres-
sion may have immediate and harmful
consequences linked to activation of the
complement system by chromatin–IgG
complexes (79). In addition, accumulated
apoptotic chromatin fragments that are
enriched in apoptosis-induced chromatin
modifications (80–82) may affect cells of
the innate immune system by triggering
TLR7–9 and the Clec4e receptor. The
apoptosis-induced chromatin modifica-
tions present in accumulated chromatin
may be involved in sustained systemic
autoimmune responses against chro-
matin (80–82).
A principal component analysis (PCA)
biplot of gene expression data from
murine (Figure 2A) and human (Figure
2B) lupus nephritis demonstrated the im-
portance of renal DNaseI gene shutdown
for progression of the inflammatory
organ disease. The data are taken from
murine and human parameters pub-
lished by Thiyagarajan et al. (68). These
PCA biplots aim to display variances of
the parameters. The angles between the
various biplot axes (shown as arrows) in-
dicate the correlations between the vari-
ables (shown as arrows). The angles be-
tween the arrows tell whether they are
clustered and indicate that they correlate
with each other. The different arrows
point at the variables. The figure, there-
fore, shows which variables are clustered
to indicate that they appear together.
Similarly, the position of the samples of
individual mice (Figure 2A, shown as the
signs 1, 2 and 3 for group 1–3 mice) and
of individual human controls and pa-
tients (Figure 2B) relative to the arrows,
indicate which variable(s) have had the
strongest impact on disease progression.
In summary, the multiple effects of extra-
cellular chromatin in lupus nephritis ag-
gravate the autoinflammatory process
that in the end will lead to end-stage
renal disease, as outlined in Figure 3.
ABERRANT RENAL DNaseI GENE
EXPRESSION IN LUPUS NEPHRITIS:
POSSIBLE REGULATORY MECHANISMS
Silencing of the DNaseI gene in kidneys
during progression of lupus nephritis
may be controlled by different mecha-
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Figure 2. PCA of murine (A) and human (B)
nephritic parameters (68). PCA biplots aim
to optimally display variances and not cor-
relations. The angles between the various
biplot axes indicate the correlations be-
tween the parameters (shown as arrows).
Similarly, the position of the samples of indi-
vidual mice (shown as the signs 1, 2 and 3
for group 1–3 mice) relative to the arrows,
indicates which variable(s) have had the
largest effect on disease progression. The
result of the biplots demonstrates that
groups emerging from this analysis perfectly
correlated with the groups of BW mice, as
defined by Licht et al. (20), defined as
prenephritic BW mice (group 1), BW mice
with deposits of EDSs in the mesangial ma-
trix (group 2) or with deposits in the GBM
(group 3). In (B), a similar biplot was gener-
ated for the human data, where the three
patients with low DNaseI expression levels
are included. The most striking observation
in these biplots is that the DNaseI vector
points away from the individuals with se-
vere lupus nephritis (to the left in the bi-
plots), demonstrating that loss of DNaseI
correlates inversely with disease progres-
sion, whereas MMP-2, MMP-9, TLRs and EDSs
associated with GBM are clustered and
points at the most severely diseased murine
and human individuals, in harmony with
statistical analyses demonstrated by 
Thiyagarajan et al. (68). This figure is modi-
fied from Thiyagarajan et al. (68).
nisms. One possibility is a direct effect of
early inflammation and secretion of
proinflammatory cytokines in the context
of early mesangial nephritis (studies in
progress). By inspection of the DNaseI
gene organization in the University of
California, Santa Cruz, genome browser
(http://genome.ucsc. edu/ index. html),
we found an overlap of 59 nucleotides in
the annotated transcript with a transcript
from the convergently transcribed tumor
necrosis factor  receptor–associated pro-
tein 1 (Trap1) gene in the 3′-untranslated
regions. This gene organization is pecu-
liar and is likely to preclude coexpression
of the two genes. Given the fact that tran-
scription proceeds well beyond the 3′ end
of the mature transcript (83,84), the over-
lap between the transcripts of the two
genes is substantial, and recent data dem-
onstrate that it is unlikely that the two
genes can be transcribed simultaneously.
This was directly demonstrated by
 Hobson et al. (85) when they analyzed
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Figure 3. The role of extracellular chromatin fragments and anti-dsDNA antibodies in progressive lupus nephritis. Retention of chromatin is as-
sumed to start with reduced clearance of apoptotic cells (station 1). Secondary to this, chromatin may be exposed in tissues (station 2) and
is assumed to activate dendritic cells (station 3). These cells present chromatin-derived peptides in the context of MHC class II molecules to
peptide-specific CD4+ T cells (station 4). When primed, the peptide-specific T cells recirculate and bind the same chromatin- derived pep-
tides presented in the context of MHC class II by chromatin-specific B-cells (here recognizing dsDNA in chromatin; station 5). As a conse-
quence of cognate interaction of dsDNA-specific B cells and peptide-specific CD4+ T cells, the B cells transform into plasma cells that se-
crete IgG anti-dsDNA antibodies (station 6), which bind chromatin fragments (station 7). Immune complexes that consist of IgG antibodies
and chromatin fragments bind in the glomerular mesangial matrix and initiate mesangial lupus nephritis (station 8). This early inflammation is
followed by silencing of renal DnaseI in tubular and glomerular cells (station 9) and accumulation of undigested chromatin fragments (sta-
tion 10). These fragments promote upregulation of TLRs, proinflammatory cytokines and matrix metalloproteases (station 11). Finally, IgG au-
toantibodies recognize and bind the chromatin fragments, and these immune complexes deposit in the GBMs and aggravate renal inflam-
mation (station 12). In this sense, chromatin fragments and anti-chromatin (here: anti-dsDNA) antibodies are the partners that impose the
classic murine and human lupus nephritis. Thus, anti-chromatin antibodies are pathogenic only in the context of exposed chromatin struc-
tures. This model does not exclude other processes that can initiate and maintain lupus nephritis, as discussed in the text.
transcription of convergent gene pairs.
They used a combination of biochemical
and genetic approaches and demon-
strated that polymerases transcribing op-
posite and overlapping DNA strands can-
not bypass each other. On the contrary,
RNA polymerase II (RNAPII) molecules
stop, and most importantly, do not disso-
ciate from the DNA strands on head-to-
head collision (85). This result suggests
that opposing polymerases represent in-
surmountable blockades for each other
(85). Finally, RNAPII induces chromatin
modification, such as specific histone
methylation and deacetylation, through
the Set2/Rpd3S pathway (86,87). Such
modifications will result in low to no ex-
pression of both genes.
The mutual suppression of one gene
by expression of the other is called tran-
scriptional interference (88). Recently, we
showed that transcription of the DNaseI
gene is inversely affected by Trap1 gene
expression (89). More detailed analyses
on regulation of DNaseI gene expression
and the role of transcriptional interfer-
ence with Trap1 gene expression are cur-
rently performed in our laboratory, in-
volving studies of other regulators of
DNaseI gene transcription such as
miRNA (manuscript in preparation, KD
Horvei, D Thiyagarajan, S Fismen, OP
Rekvig, SD Johansen, H Nielsen) and the
effect of DNA methylation.
ORIGIN OF EXPOSED GLOMERULAR
CHROMATIN
The processes that lead to exposure of
renal chromatin are still an unresolved.
Accelerated apoptosis or impaired clear-
ance of apoptotic cells is thought to be
involved (90–92). However, despite in-
tensive investigations during the last
decade, existing data on problems linked
to disturbed apoptosis or clearance of
apoptotic cells are not conclusive. Recent
data expand our insight into these
processes, since it was demonstrated that
a loss-of-function variant in DNase1L3
causes a familial form of SLE with lupus
nephritis (93). DNase1L3 is an apoptotic
endonuclease predominantly expressed
in macrophages (94) and dendritic cells
(see http://biogps.org) and therefore
links an inactive apoptotic executer to a
possible cause of lupus nephritis.
The cellular origin of chromatin frag-
ments exposed in glomeruli in the con-
text of lupus nephritis is difficult to as-
sess. Accumulation of chromatin
fragments in the GBM correlates in time
with the loss of expression of the most
important renal endonuclease (that is,
DNaseI), and this result suggests a renal
origin of the chromatin fragments. The
fact that chromatin found in the GBM in
human lupus nephritis can contain the
polyomavirus BK large T antigen (95,96)
also suggests a renal origin, since the BK
virus possesses a selective tropism for tu-
bular cells (97).
Another possibility is that that chro-
matin fragments reach glomeruli through
the circulation, eventually in complex
with IgG (40,63,98). This result explains
the systemic character of tissue damage
in SLE. Comparative studies of compo-
nents of immune complexes and their lo-
calization in skin and glomerulus mem-
branes and matrices demonstrated that
they have similar structure (99,100).
However, deposition of immune com-
plexes in glomeruli did not predict depo-
sition in skin. Examination of DNaseI
and MMP expression in the skin in 
MRL-lpr/lpr mice demonstrated a stable
activity of DNaseI and an increase in
MMP-2 and MMP-9 enzyme activities
during disease progression (100). These
results indicate that circulating immune
complexes can impose SLE manifestation
in different organs, while progression of
lupus nephritis may be organ-restricted
because of the secondary mechanisms
linked to silencing of the renal DNaseI
gene.
CONCLUSION
There is comprehensive and coherent
support for a model of lupus nephritis in
which extracellular chromatin plays a di-
rect role as a target structure for anti-
dsDNA/anti-chromatin antibodies. Thus,
a notable change in thinking entailed by
recent studies is that chromatin frag-
ments exposed in glomeruli are released
from dying renal cells and that these frag-
ments are not appropriately degraded
during the programmed cell death pro-
cess because of an acquired loss of the
dominant renal endonuclease DNaseI. In
this situation, accumulated chromatin
fragments may be targeted by potentially
nephritogenic anti-chromatin antibodies.
In this sense, interaction of the antibodies
and the chromatin targets is a homolo-
gous interaction. Therefore, the core na-
ture of both murine and human lupus
nephritis may point at exposure of chro-
matin in glomeruli and its complex for-
mation with IgG as key events in disease
pathogenesis and disease progression.
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